University of Cambridge claims to have successfully tested a vaccine containing an AI-designed antigen

University of Cambridge announced that AI successfully tested antigen vac s

This "super antigen" can provide long-term defenses for various diseases spread by humans.

There is no doubt that even if the role of AI in the future of humanity is in any position, it proves that AI is useful in the field of medical research. At present, the research team at the University of Cambridge used this technology to create a so-called universal vac。 that can be used to prevent future pandemic before spreading. It is the first time that vac s containing active ingredients designed entirely by computers were used in human clinical trials, and no significant side effects were reported.

This vac、 was vaccinated by 39 healthy volunteers aged 18-50 at two healthcare facilities in Southampton and Cambridge. This was designed to protect people from many of the Sarveco Coronavirus, a group of viruses including SARS-CoV-2, which was the cause of the global new coronavirus pandemic in 2020.

This groundbreaking antigen (efficacy of the vac。) caused the immune response of volunteers against SARS-CoV-2, SARS, and even related bat virus that may cause pandemic in the future. The vac may also provide defenses against diseases that have not yet appeared from its development method.

most vac s that are developed in response to trends and are str ling to respond to virus mutations, this new "super-antigen" can provide an all-in-one solution to diseases that jump over between humans, such as blood pressure and cerola bleeding heat.

Dr. Jonathan Heney, Professor of Virological Commons, University of Cambridge, who led the research, switched to vac。 development from post-regulatory to future vac。 development. “Our vac will continue to defend even if the virus changes to a new strain.” "We have overcome traditional vac、 problems with limited protection." This means that as the dog follows the tail, it is escaped from a constant cycle of updating the vac。 to catch up with the virus mutations that are prevalent in the human body and catch up with it.

In order to create this, the research team has entered all the available gene sequence data of the Salveco Coronavirus, recorded around the world into the AI model. Next, using machine learning, we designed antigens that contain features that are common to the entire group of viruses.

Since the sample size was relatively small, the next stage of the study will be given a vac。 to a wider variety of participants and evaluate its effectiveness again.